SVAS BIOSANA S.P.A. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8 EUR | -0.62% |
|
-0.62% | 0.00% |
| May. 10 | Mib rises above 34,500; Iveco leads rises | AN |
| May. 09 | Svas Biosana increases revenues by single digits in first quarter | AN |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 86.8 | 54.58 | 43.19 | 43.46 | - |
| Enterprise Value (EV) 1 | 103.8 | 76.24 | 43.19 | 70.96 | 68.86 |
| P/E ratio | 38.8 x | - | - | 7.19 x | 6.29 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 1.07 x | 0.56 x | 0.37 x | 0.35 x | 0.34 x |
| EV / Revenue | 1.28 x | 0.78 x | 0.37 x | 0.57 x | 0.53 x |
| EV / EBITDA | 9.75 x | 6.41 x | 3.03 x | 4.27 x | 3.87 x |
| EV / FCF | -30.7 x | 40.1 x | - | -177 x | 32.8 x |
| FCF Yield | -3.26% | 2.49% | - | -0.56% | 3.05% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 5,600 | 5,569 | 5,398 | 5,398 | - |
| Reference price 2 | 15.50 | 9.800 | 8.000 | 8.050 | 8.050 |
| Announcement Date | 4/14/22 | 4/14/23 | 5/1/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 76 | 81.09 | 97.23 | 118.3 | 123.5 | 129.5 |
| EBITDA 1 | - | 10.65 | 11.9 | 14.25 | 16.6 | 17.8 |
| EBIT 1 | - | 5.771 | 6.257 | 8.567 | 10.1 | 11.2 |
| Operating Margin | - | 7.12% | 6.44% | 7.24% | 8.18% | 8.65% |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income 1 | 2.514 | 3.161 | 3.571 | 5.123 | 6.3 | 7.1 |
| Net margin | 3.31% | 3.9% | 3.67% | 4.33% | 5.1% | 5.48% |
| EPS 2 | - | 0.4000 | - | - | 1.120 | 1.280 |
| Free Cash Flow 1 | - | -3.381 | 1.899 | - | -0.4 | 2.1 |
| FCF margin | - | -4.17% | 1.95% | - | -0.32% | 1.62% |
| FCF Conversion (EBITDA) | - | - | 15.96% | - | - | 11.8% |
| FCF Conversion (Net income) | - | - | 53.17% | - | - | 29.58% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/9/22 | 4/14/22 | 4/14/23 | 5/1/24 | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 17 | 21.7 | - | 27.5 | 25.4 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 1.598 x | 1.821 x | - | 1.657 x | 1.427 x |
| Free Cash Flow 1 | - | -3.38 | 1.9 | - | -0.4 | 2.1 |
| ROE (net income / shareholders' equity) | - | 8.03% | 6.77% | - | 9.6% | 9.8% |
| ROA (Net income/ Total Assets) | - | 2.59% | 2.53% | - | 3.5% | 3.8% |
| Assets 1 | - | 122 | 141.1 | - | 180 | 186.8 |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 5.92 | 2.99 | - | 9.1 | 9.1 |
| Capex / Sales | - | 7.3% | 3.07% | - | 7.37% | 7.03% |
| Announcement Date | 3/9/22 | 4/14/22 | 4/14/23 | 5/1/24 | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
8.05
EUR
Average target price
14.2
EUR
Spread / Average Target
+76.40%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 47.09M | |
| -4.77% | 182B | |
| +4.10% | 114B | |
| -3.85% | 67.76B | |
| +5.19% | 51.91B | |
| +5.54% | 43.23B | |
| +6.07% | 41.07B | |
| +23.81% | 32.07B | |
| +15.86% | 25B | |
| -5.06% | 24.35B |
- Stock Market
- Equities
- SVS Stock
- Financials Svas Biosana S.p.A.
